1. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Issue 12 (December 2015) Authors: Imagawa, Jun; Tanaka, Hideo; Okada, Masaya; Nakamae, Hirohisa; Hino, Masayuki; Murai, Kazunori; Ishida, Yoji; Kumagai, Takashi; Sato, Seiichi; Ohashi, Kazuteru; Sakamaki, Hisashi; Wakita, Hisashi; Uoshima, Nobuhiko; Nakagawa, Yasunori; Minami, Yosuke; Ogasawara, Masahiro; Takeoka, Tomoharu; Akasa... Journal: Lancet Issue: Volume 2:Issue 12(2015) Page Start: e528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗